Drug details

Mavyret (glecaprevir and pibrentasvir)

type of HCV NS5A Inhibitors, HCV NS3/4A Protease Inhibitors

Mavyret (glecaprevir and pibrentasvir) tablets are a fixed-dose combination of a hepatitis C virus (HCV) NS3/4A protease inhibitor and an HCV NS5A inhibitor, indicated for the treatment of patients with chronic HCV genotype (GT) 1, 2, 3, 4, 5 or 6 infection without cirrhosis and with compensated cirrhosis (Child-Pugh A). Mavyret is also indicated for the treatment of adult patients with HCV genotype 1 infection, who previously have been treated with a regimen containing an HCV NS5A inhibitor or an NS3/4A protease inhibitor, but not both.

The drug is often used to treat Cirrhosis , Hepatitis C .

This drug may have the following side effects:

• hives,
• difficulty breathing,
• severe dizziness
• swelling of your face, lips, tongue, or throat, and

The following drugs are related to Mavyret, either as a replacement or used together:

• Hepsera (adefovir dipivoxil)
• Baraclude (entecavir)
• Epivir (lamivudine)
• Epivir-HBV (lamivudine tablets and oral solution)
• Intron A (interferon alfa-2b, recombinant for injection)
• Moderiba (ribavirin tablets)
• Tyzeka (telbivudine)
• Viread (tenofovir disoproxil fumarate)